GSK files MAA for gene therapy in ultra-rare disease ADA-SCID

DUBLIN – Bidding to become the second European firm to win a gene therapy approval, Glaxosmithkline plc filed a marketing authorization application with the EMA for GSK2696273, a treatment for severe combined immunodeficiency syndrome associated with ADA-SCID in patients for whom bone marrow transplants are not possible.